Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK729327 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GSK729327 | EXPERIMENTAL | Dose escalation from 1.0mg to 6 mg. |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GSK729327 | DRUG | Tablets |
| Placebo | DRUG | GSK729327 Matching placebo - Tablets |
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 55 years inclusive. * Part B also includes healthy female subjects of non-child bearing potential. * A normal ECG, physical examination and laboratory screen. * Body weight \>50 kg and BMI within the range 18.5-29.9 kg/m2 inclus...
GSK729327 is an investigational small molecule being developed for the treatment of schizophrenia. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to evaluate its safety and tolerability.
GSK729327 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers.
GSK729327 is in Phase 1 clinical development. A Phase 1 trial has been completed, involving 79 healthy volunteers. The drug remains investigational and has not received regulatory approval for the treatment of schizophrenia or any other condition.
GSK729327 has one completed clinical trial, registered as NCT00448890, titled 'Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers.' This Phase 1 study enrolled 79 participants in Germany and the United Kingdom and was placebo-controlled.
GSK729327 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for schizophrenia. The completed Phase 1 trial was designed to evaluate safety and tolerability in healthy volunteers, and further clinical studies would be needed before any approval.